Dr. Vikram David Durairaj, MD

Dr. Durairaj practices at Texas Oculoplastic Consultants PLLC in Austin, Texas.

Dr. Durairaj's NPI, 1871683540, was assigned on October 13, 2006. Dr. Durairaj graduated from Joe R. & Teresa Lozano Long School of Medicine in 1995. Dr. Durairaj holds Texas license P8128.

Dr. Durairaj's primary practice is Texas Oculoplastic Consultants PLLC, at 3705 Medical Pkwy, Austin, TX 78705 in Travis County. The practice phone is (512) 458-2141.

Dr. Durairaj's primary practice is Texas Oculoplastic Consultants PLLC in Austin, Texas. Dr. Durairaj is also affiliated with Ascension Seton Medical Center Austin. Dmand AI also links Dr. Durairaj to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Durairaj practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Durairaj's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Durairaj is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Durairaj's licenses on file in 3 states: Texas, Colorado and Minnesota.

Dmand AI lists dry eye and eyelid inflammation among the conditions Dr. Durairaj treats.

CMS data shows 1,644 Medicare services from Dr. Durairaj across 15 procedure codes in 2024, for 398 Medicare patients. Medicare paid $170,725 for them.

CMS counts 398 Medicare patients who saw Dr. Durairaj in 2024. The largest group is 65 to 74, with 202 patients. 75% of them have high cholesterol, and 59% have high blood pressure. Their average risk score is 0.90, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Durairaj's median patient age at 68, with 60% women.

In 2024, Dr. Durairaj wrote 774 Medicare Part D claims for 364 patients. 89% of them were for generic drugs. CMS names the drug for 735 of them, across 7 drugs with 11 or more claims each, at $7,032 in total drug cost. In 2023, CMS named 694 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 58 out of 100 for Dr. Durairaj for performance year 2024, reported individually. Dr. Durairaj accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 16 procedures of melanoma (skin cancer) excision by Dr. Durairaj, more than 71% of the clinicians it reports for that procedure.

Dmand AI links 86 papers to Dr. Durairaj, published from 2006 to 2022. 2014 was the busiest year, with 6. The most frequent topics are Tomography, X-Ray Computed, Eyelids and Magnetic Resonance Imaging. Dr. Durairaj has published most often in Ophthalmic Plast Reconstr Surg. Dr. Durairaj's most frequent co-authors are Vikram Durairaj, MD, Brett W. Davies, MD and Eric Michael Hink, MD.

CMS Open Payments shows 618 general payments to Dr. Durairaj from 33 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. Stryker Corporation paid the most, $442,755.

Dmand AI lists 3 awards for Dr. Durairaj, most recently CMS Stage 1 EHR in 2013.

Dr. Durairaj graduated from Joe R. & Teresa Lozano Long School of Medicine in 1995. Dr. Durairaj is a member of AAO and ACS.

Dr. Durairaj is in network with 21 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.